Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28438373 | 0.91 | DNM1 (0.40) | TDP1PCSK9LTA4HCES2CES1 | |
| SCHEMBL2850629 | 0.81 | TDP1 (0.38) | TDP1PCSK9LTA4HPTGS2CES2 | |
| SCHEMBL11028855 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL9568181 | 0.74 | TP53 (0.41) | TDP1PCSK9LTA4HCES2CES1 | |
| SCHEMBL27583072 | 0.73 | DNM1 (0.40) | LTA4HCES2CES1SMN1; SMN2SIGMAR1 | |
| SCHEMBL9746250 | 0.73 | PCSK9 (0.36) | TDP1PCSK9LTA4HPTGS2CES2 | |
| Toluene SCHEMBL27536751 | 0.70 | TSHR (0.50) | PCSK9LTA4HPTGS2CES2CES1 | |
| Benzenethiol SCHEMBL9622099 | 0.68 | LTA4H (0.35) | TDP1PCSK9LTA4HPTGS2CES2 | |
| SCHEMBL9720431 | 0.68 | TP53 (0.42) | SMN1; SMN2SIGMAR1TP53 | |
| SCHEMBL10739965 | 0.68 | TP53 (0.42) | SMN1; SMN2SIGMAR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781610-B2 | Heterogeneous organotin catalysts | CHEMTURA CORPORATION (US) | 2010-08-24 | — | — | US | disclosed |
| US-7772417-B2 | Heterogeneous organotin catalysts | CHEMTURA CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100174106-A1 | HETEROGENEOUS ORGANOTIN CATALYSTS | CHEMTURA CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100152477-A1 | HETEROGENEOUS ORGANOTIN CATALYSTS | CHEMTURA CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-7687581-B2 | Heterogeneous organotin catalysts | CHEMTURA CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1598381-B1 | Heterogeneous organotin catalysts | CHEMTURA ORGANOMETALLICS GMBH (DE) | 2006-10-18 | — | — | EP | disclosed |
| CN-1714935-A | Heterogeneous organotin catalysts | CROMPTON GMBH (DE) | 2006-01-04 | — | — | CN | disclosed |
| US-20050261444-A1 | Heterogeneous organotin catalysts | GLCC LAUREL, LLC | 2005-11-24 | — | — | US | disclosed |
| EP-1598381-A1 | Heterogeneous organotin catalysts | Crompton GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-5194365-A | Method for forming images | CIBA-GEIGY CORPORATION (US) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174106-A1 | HETEROGENEOUS ORGANOTIN CATALYSTS | ATXN2L, CDYL, ZYX | TDP1 3740/4885PCSK9 4743/4885LTA4H 1418/4885 |
| US-20100152477-A1 | HETEROGENEOUS ORGANOTIN CATALYSTS | ATXN2L, CDYL, ZYX | TDP1 3740/4885PCSK9 4743/4885LTA4H 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.